Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lucia Festino
Observed names:
Festino Lucia,
Festino, Lucia,
L. Festino
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
University of Campania "Luigi Vanvitelli",
Seoul National University Hospital,
Ospedale Antonio Cardarelli,
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0002-3035-266X
Observed ORCID:
0000-0002-3035-266X
OpenAlex ID:
A5048209523
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
2018
·
Mariaelena Capone
, Diana Giannarelli
, et al.
·
Journal for ImmunoTherapy of Cancer
·
542
PDF
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
2016
·
Lucia Festino
, Gerardo Botti
, et al.
·
Drugs
·
153
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors
2017
·
Antonio M. Grimaldi
, Ester Simeone
, et al.
·
American Journal of Clinical Dermatology
·
152
PD-L1 expression as a potential predictive biomarker
2015
·
Alberto Fusi
, Lucia Festino
, et al.
·
The Lancet Oncology
·
121
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
2015
·
Nicola Mozzillo
, Ester Simeone
, et al.
·
OncoImmunology
·
93
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
2017
·
Ester Simeone
, Antonio M. Grimaldi
, et al.
·
BioDrugs
·
71
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
2021
·
M. Guida
, S. Strippoli
, et al.
·
ESMO Open
·
66
PDF
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
2020
·
Roberta Turiello
, Mariaelena Capone
, et al.
·
Journal for ImmunoTherapy of Cancer
·
60
PDF
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations
2019
·
Claudia Trojaniello
, Lucia Festino
, et al.
·
Expert Review of Clinical Pharmacology
·
54
Epigenetic Regulation in Melanoma: Facts and Hopes
2021
·
Emilio Francesco Giunta
, Gianluca Arrichiello
, et al.
·
Cells
·
51
PDF
Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis
2017
·
Gianluca Di Monta
, Corrado Caracò
, et al.
·
Journal of Translational Medicine
·
49
PDF
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
2016
·
Matteo S Carlino
, Vito Vanella
, et al.
·
British Journal of Cancer
·
46
PDF
PD-L1 inhibitors in the pipeline: Promise and progress
2017
·
Vito Vanella
, Lucia Festino
, et al.
·
OncoImmunology
·
44
PDF
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
2017
·
Ester Simeone
, Antonio Maria Grimaldi
, et al.
·
OncoImmunology
·
44
PDF
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
2017
·
Vera Hirsh
, Sandro Pignata
, et al.
·
Journal of Translational Medicine
·
43
PDF
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
2023
·
Xue Bai
, Ahmed Shaheen
, et al.
·
EClinicalMedicine
·
32
Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
2015
·
Antonio Maria Grimaldi
, Ester Simeone
, et al.
·
PubMed
·
32
Metformin in lung cancer: rationale for a combination therapy
2013
·
Floriana Morgillo
, Ferdinando Carlo Sasso
, et al.
·
Expert Opinion on Investigational Drugs
·
30
Management of cutaneous melanoma: radiologists challenging and risk assessment
2022
·
Vincenza Granata
, Igino Simonetti
, et al.
·
La radiologia medica
·
28
Immunotherapy in Metastatic Melanoma: A Novel Scenario of new Toxicities and their Management
2019
·
Ester Simeone
, Antonio M Grimaldi
, et al.
·
Melanoma Management
·
28
PDF
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
2019
·
Vito Vanella
, Lucia Festino
, et al.
·
Current Oncology Reports
·
28
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
2021
·
Florentia Dimitriou
, Anne Zaremba
, et al.
·
European Journal of Cancer
·
27
PDF
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
2023
·
Domenico Mallardo
, Ester Simeone
, et al.
·
Journal of Translational Medicine
·
24
PDF
Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial
2016
·
Paolo A. Ascierto
, Vito Vanella
, et al.
·
Cancer Immunology Immunotherapy
·
22
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
2022
·
Domenico Mallardo
, Diana Giannarelli
, et al.
·
Journal for ImmunoTherapy of Cancer
·
21
PDF
Show more works
View as search
Works count:
106
Citation count:
2,158
H-index:
23
I10-index:
39
Year
Topic
Type